Collecting tumor tissue samples from patients undergoing surgery or biopsy for cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to collect tissue samples from patients with solid tumors who are scheduled for surgical procedures or biopsies at the National Institutes of Health Clinical Center. The collected samples will be used to identify novel molecular and biologic therapeutic targets that could lead to new cancer treatments. Participants will also have a small blood sample taken, and some may undergo leukapheresis. The study focuses on various types of cancers, including colorectal, gastric, and pancreatic neoplasms.

Why it matters

Who can join: the full rules

* INCLUSION CRITERIA:
* Participants must be 2 years of age or older. Note: Participants greater than or equal to 2 and \< 18 years of age may only participate in research sample collection if the tissue acquisition is performed during a clinically indicated surgical procedure, and the biospecimen sampling (e.g., blood, urine, ascites, bile, or \[clinically indicated\] resected tumor tissue) does not add risk to the clinically indicated procedures.
* Participants who have premalignant, primary, or metastatic solid tumors based upon either radiographic or clinical suspicion, biochemical testing, a genetic predisposition, or histological/cytological analysis that requires surgery or biopsy as part of the diagnosis, prevention, treatment, and/or follow-up.
* Participants without solid tumors in whom a diagnostic, preventative, or therapeutic intervention is being performed, but for whom surgical quality and safety outcomes data are generated.
* Participants should have laboratory and physical examination parameters within acceptable limits prior to biopsy or surgery.
* Participants must be planning to undergo surgery or biopsy as part of their normal treatment plan.
* Ability of participant, parent/guardian or legally authorized representative (LAR) to understand and the willingness to sign a written informed consent document.

EXCLUSION CRITERIA:

None.

Where it's running

• National Institutes of Health Clinical Center
  Bethesda, Maryland, United States Recruiting

Study contacts

• Principal investigator: Jonathan M Hernandez, M.D. — National Cancer Institute (NCI)
• Study coordinator: Cathleen E Hannah, C.R.N.P.
• Email: foregut@mail.nih.gov
• Phone: (240) 858-7006

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining PDS01ADC with targeted liver chemotherapy for certain cancers

  This study is testing if a new cancer treatment that combines an immune booster with targeted liver chemotherapy can help people with certain advanced cancers feel better and live longer.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT05286814

• LY4337713 for people with FAP-positive ovarian, breast, pancreatic, colorectal, or esophageal cancers

  This trial tests LY4337713, a FAP-targeted lutetium-177 therapy, in people with advanced cancers that show high levels of fibroblast activation protein (FAP).

  Recruiting at 17 sites Phase 1 Eli Lilly and Company · Newport Beach, California and 29 other locations · NCT07213791

• Tissue adhesive (Glubran®2) to reinforce pancreaticojejunostomy in soft pancreas

  This trial will test whether adding a tissue adhesive glue (Glubran®2) to the pancreatic-jejunal connection reduces postoperative pancreatic leaks in adults with a soft pancreas undergoing pancreaticoduodenectomy.

  Recruiting Minia University · Minya, Minya Governorate · NCT07155525

• Neoadjuvant tislelizumab with SBRT and gemcitabine/platinum chemotherapy for borderline or unresectable hilar bile duct cancer

  This trial will see if precise radiotherapy (SBRT) followed by the PD‑1 drug tislelizumab plus gemcitabine and platinum chemotherapy can shrink tumors enough to allow surgery and improve survival in people with borderline resectable or unresectable hilar cholangiocarcinoma.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT07030140

• Evaluating eccDNAs as biomarkers for diagnosing biliary stricture

  This study is testing if a new type of DNA found in the blood can help doctors better diagnose patients with unclear bile duct blockages, especially to catch cancer earlier.

  Recruiting at 2 sites Peking University Third Hospital · Beijing, Beijing Municipality and 1 other locations · NCT06277531

• Endoscopic radiofrequency ablation for unresectable bile duct cancer

  This study tests whether adding intraductal radiofrequency ablation to standard chemotherapy and bile duct stenting helps people with unresectable bile duct cancer.

  Recruiting at 9 sites Universitätsklinikum Hamburg-Eppendorf · Berlin and 8 other locations · NCT06175845

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.